In a June 10 story about diabetes treatment research, The Associated Press reported erroneously that LY2605541 is a short-acting insulin. It is a long-acting insulin.
Also, Johnson & Johnson applied for U.S. approval to sell its experimental diabetes pill canagliflozin on May 31, not May 29.
Crime Wave: Murders Skyrocket Across The Country in St. Louis, Milwaukee, Chicago, Atlanta, New York City | Katie Pavlich
Obama Apparently Thinks He's the 'Closest Thing to a Jew That Has Ever Sat in This Office’ | Leah Barkoukis